Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingPhase 1 Phase I Clinical Trial on Safety, Tolerability and Immunogenicity of HIV Therapeutic DNA Vaccine (ICVAX) in Clinically Stable HIV Patients Under ART
The clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically stable HIV patients under ART treatment.
100 Clinical Results associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
0 Patents (Medical) associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
100 Deals associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
100 Translational Medicine associated with Shenzhen Immuno Cure Biomedical Co., Ltd.